Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Investor Presentation (July 2026)
5 slides from Oncotelic Therapeutics's investor presentation, Jul 14, 2026
Slide 1: Building the Next Era of Precision Therapeutics
(a ) Therapeutics Innovating Today for a Hoalthior Tomorrow Oncotelic Al-DRIVEN. CLINICALLY VALIDATED. QUANTUM-ACCELERATED. BUILDING THE NEXT ERA OF PRECISION THERAPEUTICS A next-generation biotech company on par — or beyond ~ In Silico Medicine. @ 2OINT VENTURE PROGRAMS ~ SAPU FAMILY OF COMPANIES @
Slide 2: Nose-to-Brain Delivery Pathways
NOSE-TO-BRAIN DELIVERY PATHWAYS: > factory Pathway Direct transport along factory neuron othe ‘factory bulb ana > Tigeminal Pathwey Transport along tigeminal nerve branches tothe brsirctom and CNS systemic Pathway ‘Abzorption ito eystomie ‘Seclaion wth nd bran clvery CATEGORY bain y caf, APOMORPHINE
Slide 3: LNAI-Oncotelic Biodefense Program
LNAI LNAI-ONCOTELIC BIODEFENSE PROGRAM | Oncoretic THERAPEUTICS CNS RESILIENCE NON-INVASIVE + RAPID + BRAIN-DIRECTED + LIFE-SAVING + FUNCTION-RESTORING : Ke INNOVATION. PLATFORM A Staged, Intranasal Therapeutic Platform to Protect the Brain, MANUFACTURING. Preserve Function, and Accelerate Recovery
Slide 4: AI-Driven Target Discovery and Pipeline Snapshot
4 Al-DRIVEN TARGET DISCOVERY. SueeSon €) PDAOAI CLINICALLY VALIDATED. QUANTUM-ACCELERATED. G AaRinton: sad aren covet ts oather A next-generation biotech company on par — or beyond ~ In Silico Medicine. Ernie aries FOmee Portia Wark eercienl a seees WHY PDAOAI BIOTECH? ‘OUR PIPELINE SNAPSHOT 28M+ 10
Slide 5: Vuong Trieu PhD (CEO) and Management Team
Vuong Trieu PhD (CEO): Inventor of Abraxane® and Cynviloq®, two breakthrough nanoparticde oncology therapiesFounder and CEO of multiple _ public Biotechnology companies, including Oncotelic, Marina Biotech, and IgDraSol100+ patent applications and 39 issued U.S. patents spanning oncology and drug de
Oncotelic Therapeutics — Investor Presentation (July 2026) on 6ix